Association between type 1 diabetes and neurodevelopmental disorders in children and adolescents: A systematic review and meta-analysis

Xue-Ni Xie1,2, Xue Lei3, Chun-Ye Xiao4, Ya-Min Li1,* and Xian-Yang Lei5,*

1Clinical Nursing Teaching and Research Section, The Second Xiangya Hospital, Central South University, Changsha, China, 2School of Public Health, Kunming Medical University, Kunming, China, 3School of Psychology, The University of Queensland, St Lucia, QLD, Australia, 4School of Nursing, Jinan University, Guangzhou, China, 5Office of the President, Central South University, Changsha, China

Type 1 diabetes and neurodevelopmental disorders are common chronic conditions in childhood and adolescence, and having one may lead to an increased chance of developing the other. Type 1 diabetes mellitus is mainly manifested by elevated blood glucose, while neurodevelopmental diseases are composed of a variety of diseases, which are relatively complex. The purpose of this meta-analysis was to find out the prevalence of type 1 diabetes-related neurodevelopmental disorders in children and adolescents and to explore the potential association between neurodevelopmental disorders and type 1 diabetes. PubMed, Embase and Web of science databases were searched from the inception to May 22, 2022 to identify relevant studies. Finally, 24 original studies were included in the meta-analysis. Prevalence estimates for neurodevelopmental disorders in the type 1 diabetes adolescent and their 95% confidence intervals were pooled using random effects models. The pooled estimates for autism spectrum disorders (ASD) and attention deficit hyperactivity disorder (ADHD) in the type 1 diabetes population were 1.2 and 5.3%, respectively, both of which are higher than the 2019 global prevalence of ASD and ADHD in the general population. The results of the subgroup analysis showed that the prevalence of ASD and ADHD in the T1DM population tended to increase with age. In conclusion, there may be a potential link between the occurrence
of type 1 diabetes mellitus and the development of neurodevelopmental disorders in children and adolescents, but more relevant studies are needed to understand the link between the underlying pathogenesis of type 1 diabetes and neurodevelopmental disorders.

**Systematic review registration:** [https://www.crd.york.ac.uk/PROSPERO/], identifier [CDR42022333443].

**KEYWORDS**

type 1 diabetes mellitus (T1DM), neurodevelopmental disorders (NDDs), prevalence, autism spectrum disorder (ASD), meta-analysis, attention deficit hyperactivity disorder (ADHD)

**Introduction**

Neurodevelopmental disorders (NDDs) are a group of complex disorders that are not easily conceptualized. In the DSM-5, NDDs are defined as a group of disorders that occur during development, including autism spectrum disorders (ASD), attention deficit hyperactivity disorder (ADHD), intellectual disability (ID), communication disorders (CD), specific learning disabilities (SLD), and motor disorders (MDs) (1, 2). They are characterized by childhood onset with delays in developmental domains such as cognition, executive functioning, language/communication, social functioning, and adaptive behavior (3), besides, people with ASD also have social and interaction difficulties (4). There are gender differences in the onset of NDDs. The diagnosis rate of males is higher than that of females, and the onset risk of males is 2–4 times higher than that of females (5–8). Regarding to the most common NDDs, previous studies published specific prevalence: 1/6 (17.4%) of American children aged 2–8 suffer from mental, behavioral or developmental disorders (9). In 2018, the global average prevalence of ADHD in school-age children was 5% (range: 2–7%) (10). In addition, according to the Centers for Disease Control, the prevalence of ASD among 8-year-olds in the United States increased from 0.67% in 2000 and 2002 to 2.3% in 2018 (11–13). The additional health, social care and education costs associated with childhood mental illness were estimated at £1.47 billion in 2008 in Britain, which impose a significant social and economic burden (14–16). Furthermore, mental disorders are listed as one of the top 10 causes of the global burden (17) and are seen as a major contributor to the burden of disease (18). Therefore, it is suggested to investigate causal pathways between mental disorders and other severe health issues.

Diabetes is another chronic disease that can be extremely dangerous, which can seriously damage many systems of the body, especially nerves and blood vessels. It is defined as a group of metabolic diseases characterized by hyperglycemia caused by defective insulin secretion, defective insulin action or both. There are two types of diabetes, type 1 diabetes mellitus (T1DM) and type 2 diabetes (19). The prevalence of diabetes is increasing year by year, with 451 million adults worldwide living with diabetes as of 2017, and the number is expected to rise to 693 million by 2045 (20).

Type 1 diabetes is characterized by elevated blood glucose levels due to insulin deficiency caused by loss of pancreatic b-cells, and it is a common chronic disease in children and adolescents, along with mental disorders (2, 21, 22). Studies have shown that T1DM brings great psychological burden to children and adolescents, and greatly increases the risk of mental health problems (23–25). NDDs are more common in children with T1DM compared to the general population (26–28). Vice versa, NDDs may also affect blood glucose control and increase the risk of diabetes complications (29). The International Society for Pediatric and Adolescent Diabetes (ISPAD) notes that mental health problems can lead to serious impacts and long-term consequences in young people with T1DM (30). However, no comprehensive study has examined the relationship between NDDs and T1DM in children and adolescents.

NDDs and T1DM are common in children and adolescents, may have similar pathogenesis, and may occur together. The purpose of this study was to investigate the prevalence of T1DM and NDDs in children and adolescents through meta-analysis and to explore the potential association between these two diseases.

**Materials and methods**

The Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guideline were followed by this systematic review (31). The protocol has been registered in PROSPERO (CDR42022333443).

**Search strategy**

We searched Embase, PubMed, and Web of Science databases for relevant articles published as of May 22, 2022. We selected subject terms and keywords related to diabetes, autism, ADHD, ID, CD, SLD, and motor disabilities in different databases, and the detailed retrieval strategy is shown in
Supplementary Table 1. Additional studies were identified by manually reviewing of the references of included studies. The study selection process was completed independently by two researchers (X.L. and XN.-X.).

Study inclusion criteria

The inclusion criteria of the studies were as follows: (a) the age of population was 18 years old or below; (b) the population is accompanied by T1DM with NDDs or NDDs with T1DM; (c) The reported study must be published in English; (d) Prevalence estimates or raw data can be used to calculate the prevalence are available in the study; (e) The study to be included must be original studies, and reviews or systematic reviews are excluded. All papers that meet the criteria will be included in the systematic review.

Data extraction and quality assessment

A standardized form was used to extract the following data from the included studies: Author and year of publication, study content (country, study setting, data source, study period, sample size, age, percentage of males), diagnosis and criteria of T1DM and NDDs, outcome (the prevalence of NDDs in T1DM or the prevalence of T1DM in NDDs). If the prevalence estimates were not directly provided in the study, raw data from the article are collected and calculated to obtain prevalence. In addition, we also extracted the types of scales used in the diagnosis of different diseases and the judgment criteria used in the table, which are respectively, expressed as diagnosis and criteria in the table header (Supplementary Table 2). Two researchers (X.L. and XN.-X.) extracted data independently, and disagreements, if any, were resolved through discussion with the third author (YM.-L).

The 14-item rating scale National Institutes of Health Study Quality Assessment Tool for Observational Cohort and Cross-sectional Studies were used to assess the quality of each included study. The quality assessment was performed independently by two researchers (X.L. and XN.-X.) and resolved by negotiation or discussion with the third author (XY.-L).

Statistical analysis

The main outcome of this meta-analysis summarizes the prevalence of NDDs in individuals with type 1 diabetes. Data from people with T1DM with NDDs were analyzed for comparison. Prevalence estimates in each study were weighted by sample size and number of cases and then pooled through meta-analysis. $I^2$ statistics were used to evaluate heterogeneity between studies (32). $I^2$-value less than 30% was considered as low heterogeneity, greater than 60% was interpreted as substantial heterogeneity, and between 30 and 60% was considered as moderate heterogeneity. Publication bias was assessed by visually observing the symmetry of funnel plots and quantiative Egger (33) and Begg (34) tests. If publication bias is found, Duval Tweedie’s “trim and fill” method is used to obtain adjusted estimates (fill estimates) (35). We also looked at the study setting (population-based, clinically based), geographic region (North America, Asia, Europe, Africa), survey period (≤2010, >2010), age range (2–12 years old, ≥13 years old) and diagnosis/criteria (single standard, both standard). All statistical analyses were performed using Stata 17.0 software.

Results

Study selection and characteristics

The PRISMA diagram for studying the selection process is shown in Figure 1. Among the retrieved studies, a total of 31 met the inclusion criteria (28 were related to NDDs in T1DM, and 3 were related to T1DM in NDDs) and were included in the systematic review. In the included studies, we excluded studies from the same investigation sources and studies related to T1DM in NDDs that were too small to be meta-analyzed. Finally, 24 studies related to NDDs in T1DM were included in the meta-analysis.

All of the studies were conducted between 1973 and 2019, with 20 population-based studies and 11 clinical-based studies (Supplementary Tables 2, 3). As part of the included papers were conference papers, the total number of papers participating in the quality evaluation was 21. The NIHSQAT (National Institutes of Health Research Quality Assessment Tool) was used to score the quality of all articles included in the analysis with full text, with all articles between 6 and 10 points in quality. A total of four items (20.0%) were rated as excellent (≥10 points) and 16 items (80.0%) were rated as fair (≥6 points). The results of the quality assessment are presented in detail in Supplementary Tables 4, 5.

Autism spectrum disorders/deficit hyperactivity disorder in children and adolescents with type 1 diabetes

Studies on the T1DM and ASD sample were published between 1973 and 2017 and included three clinically based studies and eight population-based studies (22, 23, 26, 36–44). Four studies were conducted in North America, six in Europe. Studies on a sample of patients with T1DM and ADHD, both published between 1973 and 2019, included 14 population-based studies and seven clinically based studies (19, 20, 23, 26,
Papers identified through database searching (n = 16032)

Additional papers identified through other sources (n = 1)

Papers after duplicates removed (n = 14202)

Papers screened (n = 14202)

Papers of irrelevant topics excluded (n = 14098)

Papers excluded (n = 73)
  - Subjects were not combined with neurodevelopmental disorders and T1DM (n = 10)
  - The literature type is review (n = 5)
  - Without sufficient data for prevalence calculation (n = 41)
  - The patients are not adolescents (n = 17)

Full-text papers assessed for eligibility (n = 104)

Papers excluded (n = 73)
  - Subjects were not combined with neurodevelopmental disorders and T1DM (n = 10)
  - The literature type is review (n = 5)
  - Without sufficient data for prevalence calculation (n = 41)
  - The patients are not adolescents (n = 17)

Papers included in systematic review (n = 31)
  (NDDs in T1DM: 28)
  (T1DM in NDDs: 3)

Papers excluded (n = 7)
  - Multiple papers of same investigations (n = 4)
  - The number of T1DM in NDDs was insufficient for subgroup analysis (n = 3)

Papers included in meta-analysis (n = 24)
  (NDDs in T1DM: 24)

FIGURE 1
PRISMA flow chart.

The prevalence of ASD and ADHD in children and adolescents with T1DM was 1.2% (95%CI: 0.9–1.6%) and 5.3% (95%CI: 4.3–6.4%), respectively (Supplementary Figures 1, 2). Subgroup analysis showed that the prevalence of ASD among adolescents/children with T1DM was 1.1% in population-based studies, 6.1% in clinical studies, 1.0 and 1.3% in Europe and North America, 0.9 and 1.4% before and after 2010 and after 2010, respectively. The prevalence was 0.8% in 2–12 years and 1.4% in 13–18 years. The prevalence of ADHD was 4.8% in population studies and 7.7% in clinical studies, and 4.0% in Europe, 28.4% in North America, 17.9% in Asia and 33.3% in Africa. The prevalence in 2010 and before and after 2010 was 2.0 and 6.7%, respectively. The prevalence was 2.7% in 2–12 years and 6.7% in 13–18 years, respectively (Tables 1, 2).

Detection of publication bias by funnel plot, Begg test and Egger test (Supplementary Figures 3, 4). The fill prevalence of ADHD in the T1DM children and adolescent population obtained by the “trim and fill” method was 1.3%, whereas ASD had no fill prevalence in the T1DM adolescents.

Except ASD and ADHD, other NDDs retrieved in this study were not included in our meta-analysis.

Type 1 diabetes mellitus in children and adolescents with neurodevelopmental disorders

There were two studies on T1DM among the included children and adolescents with ASD, which were conducted in the United States from 2001 to 2010. One was a clinical study and the other was a population-based study, with a prevalence rate of 0.93 and 0.67%, respectively. The quality evaluation was of general quality. There is only one study related to T1DM in children and adolescent ADHD patients, which is a population-based study conducted in China with a prevalence rate of 0.1%, and it is rated as good quality.

Except ASD and ADHD, there is no study on type 1 diabetes in children and adolescents with other neurodevelopmental disorders that met our inclusion criteria.
| Variables                         | No. of studies | Prevalence (95%CI) | $I^2$ % | $p_{heterogeneity}$ | Egger test | Begg test | No. of missing studies | Filled prevalence (95%CI) |
|----------------------------------|----------------|--------------------|---------|---------------------|------------|-----------|-----------------------|--------------------------|
| **Analysis for ASD**             |                |                    |         |                     |            |           |                       |                          |
| Study setting                    |                |                    |         |                     |            |           |                       |                          |
| Population-based                 | 8              | 1.1 (0.7, 1.5)     | 97.3    | <.001               | 0.067      | 0.138     | 0                     | NA                       |
| Clinic-based                     | 2              | 6.1 (4.8, 17.1)    | 93.2    | <.001               | NA         | 0.317     | NA                    | NA                       |
| Geographical area                |                |                    |         |                     |            |           |                       |                          |
| North America                    | 4              | 1.3 (0.9, 1.6)     | 68.8    | 0.022               | 0.018      | 0.174     | 0                     | NA                       |
| Europe                           | 6              | 1.0 (0.6, 1.5)     | 96.7    | <.001               | 0.117      | 0.573     | 1                     | 1.0 (0.5, 1.5)           |
| Study period                     |                |                    |         |                     |            |           |                       |                          |
| ≤2010                            | 4              | 0.9 (0.6, 1.2)     | 78.8    | 0.003               | 0.294      | 0.174     | 0                     | NA                       |
| >2010                            | 2              | 1.4 (0.9, 1.9)     | 79.2    | 0.028               | NA         | 0.317     | 0                     | NA                       |
| Age                              |                |                    |         |                     |            |           |                       |                          |
| 2–12                             | 5              | 0.8 (0.3, 1.3)     | 96.7    | <.001               | 0.322      | 1.000     | 1                     | 0.7 (0.2, 1.3)           |
| 13–18                            | 2              | 1.4 (0.9, 1.9)     | 79.2    | 0.028               | NA         | 0.317     | 0                     | NA                       |
| ASD diagnosis/criteria           |                |                    |         |                     |            |           |                       |                          |
| Standard diagnosis               | 3              | 1.4 (1.0, 1.7)     | 68.3    | 0.042               | 0.171      | 0.117     | 0                     | NA                       |
| Standard criteria                | 5              | 1.1 (0.7, 1.5)     | 94.4    | <.001               | 0.255      | 0.624     | 0                     | NA                       |
| T1DM diagnosis/criteria          |                |                    |         |                     |            |           |                       |                          |
| Standard diagnosis               | 2              | 1.5 (1.2, 1.8)     | 62.4    | 0.103               | NA         | 1.000     | 0                     | NA                       |
| ADHD in T1DM populations using random-effects meta-analysis and subgroup meta-analysis. |
| Variables                         | No. of studies | Prevalence (95%CI) | $I^2$ % | $p_{heterogeneity}$ | Egger test | Begg test | No. of missing studies | Filled prevalence (95%CI) |
|----------------------------------|----------------|--------------------|---------|---------------------|------------|-----------|-----------------------|--------------------------|
| **Analysis for ADHD**            |                |                    |         |                     |            |           |                       |                          |
| Study setting                    |                |                    |         |                     |            |           |                       |                          |
| Population-based                 | 11             | 4.8 (3.5, 6.0)     | 97.0    | <.001               | 0.039      | 0.184     | 4                     | 3.5 (2.2, 4.8)           |
| Clinic-based                     | 7              | 7.7 (5.4, 10.0)    | 94.3    | <.001               | 0.009      | 0.099     | 1                     | 7.0 (4.6, 9.4)           |
| Geographical Area                |                |                    |         |                     |            |           |                       |                          |
| North America                    | 1              | 28.4 (17.4, 39.4)  | NA      | NA                  | NA         | NA        | 0                     | NA                       |
| Europe                           | 11             | 4.0 (3.0, 5.0)     | 96.8    | <.001               | 0.076      | 0.876     | 4                     | 3.1 (2.2, 4.1)           |
| Asia                             | 5              | 17.9 (6.6, 29.1)   | 96.8    | <.001               | 0.004      | 0.327     | 0                     | NA                       |
| Africa                           | 1              | 33.3 (21.4, 45.2)  | NA      | NA                  | NA         | NA        | 0                     | NA                       |
| Study period                     |                |                    |         |                     |            |           |                       |                          |
| ≤2010                            | 4              | 2.0 (0.7, 3.3)     | 98.5    | <.001               | 0.701      | 0.718     | 0                     | NA                       |
| >2010                            | 10             | 6.7 (5.0, 8.5)     | 89.5    | <.001               | 0.001      | 0.020     | 4                     | 5.0 (3.2, 6.8)           |
| Age                              |                |                    |         |                     |            |           |                       |                          |
| 2–12                             | 7              | 2.7 (1.6, 3.8)     | 92.9    | <.001               | 0.005      | 0.015     | 3                     | 1.8 (0.5, 3.1)           |
| 13–18                            | 8              | 14.2 (9.3, 19.1)   | 90.4    | <.001               | 0.015      | 0.004     | 2                     | 10.0 (4.9, 15.1)         |
| ADHD diagnosis/criteria          |                |                    |         |                     |            |           |                       |                          |
| Standard diagnosis               | 15             | 5.9 (4.8, 7.0)     | 93.6    | <.001               | 0.001      | 0.023     | 6                     | 4.5 (3.3, 5.7)           |
| Standard criteria                | 10             | 3.3 (2.3, 4.4)     | 97.4    | <.001               | 0.111      | 0.472     | 3                     | 2.7 (1.7, 3.8)           |
| T1DM diagnosis/criteria          |                |                    |         |                     |            |           |                       |                          |
| Standard diagnosis               | 8              | 4.0 (3.0, 5.0)     | 93.6    | <.001               | 0.090      | 0.266     | 3                     | 3.4 (2.2, 4.6)           |
| Standard criteria                | 9              | 6.4 (4.8, 7.9)     | 94.8    | <.001               | 0.004      | 0.251     | 4                     | 4.5 (2.9, 6.1)           |
| Standard diagnosis               | 6              | 2.5 (1.5, 3.5)     | 97.3    | <.001               | 0.154      | 0.251     | 1                     | 2.3 (1.2, 3.4)           |
| Standard diagnosis               | 3              | 3.0 (2.0, 4.0)     | 94.6    | <.001               | 0.686      | 1.000     | 0                     | NA                       |
Discussion

The results of the study showed that the prevalence of ASD and ADHD in T1DM children and adolescents was 1.1% (95% CI: 0.8–1.5) and 5.3% (95% CI: 4.3, 6.4), respectively, both higher than the global prevalence of ASD and ADHD in the general population in 2019 (0.4 and 1.1%), suggesting that T1DM has an impact on the prevalence of ASD and ADHD. Present study analyzed the prevalence of concurrent NDDs with T1DM in children and adolescents and explored the potential association between T1DM and NDDs.

A growing number of studies have explored the relationship between metabolic disorders and psychiatric disorders, and there has been a gradual increase in research on the relationship between diabetes and psychiatric disorders, as well as a large body of literature exploring the effect of maternal diabetes on the development of neurodevelopmental disorders in offspring (61–65), but the detailed mechanisms remain unclear. Meanwhile, there are fewer original studies on the comorbid psychiatric disorders in patients with T1DM. Our systematic search strategy retrieves all available studies to comprehensively summarize the current evidence. Our subgroup analysis provides evidence for the increased prevalence of ADHD from childhood to age in patients with type 1 diabetes, but the relationship between ASD prevalence and age stratification needs to be further explored. Potential solid studies were identified through the 'trim and fill' approach, which means there may be unpublished studies or less obvious results that were not included in our meta-analysis. However, the filled studies and their prevalence were not calculated by retrieval from existing data, and the 'trim and fill' method used to adjust the mixed estimates was based on funnel plots (23), so the number of filled studies may not be true, and their estimates of prevalence may not be very accurate. Three mechanisms may be involved in the relationship between type 1 diabetes and neurodevelopmental disorders (Figure 2) (66, 67): Firstly, dysregulated circulating autoantibodies (GAD-Abs). Abnormalities of GAD65 and IA-2 antibodies (Abs) can be detected in the blood of patients with both type 1 diabetes and neurodevelopmental disorders. It was reported that GAD65 and IA-2 antibodies (Abs) can be detected in the blood months to years before the onset of symptoms (68). In a study with 20 children with ASD and 15 children with ADHD, immunoassays showed that 15% of children with ASD and 17% of children with ADHD had higher serum levels of GAD65 antibodies compared to controls (69). The neurotransmitter gamma amino butyric acid (GABA) is a major neurotropic agent in the central nervous system and plays a key role in the early development of the nervous system, while GAD65 is one of the two enzymes that catalyze the formation of GABA from glutamate (70); therefore,
abnormalities in GAD65 may lead to abnormal development of the nervous system. Secondly, specific single nucleotide polymorphism (SNP) mutations. Studies have shown that SNPs are significantly associated with a range of childhood and adult-onset psychiatric disorders (71), and copy number variants identified in genome-wide studies may contribute to the risk of multiple psychiatric disorders (72). At the same time, an increasing number of SNPs are significantly associated with the pathogenesis of diabetes (73). Thirdly, Abnormal insulin and glucose concentrations. Abnormal insulin and glucose concentrations include insulin deficiency, hyperglycemia, and medically induced hypoglycemia. There is now evidence that insulin plays an important role in neurodevelopment (74), and the effects of insulin overdose and resulting severe hypoglycemia on the central nervous system during T1DM treatment may lead to neurocognitive deficits (75), but there is no clear evidence to confirm the reliability of this theory. Similar to insulin, glucose metabolism is critical for brain development and function (35), and abnormal glucose in children with type 1 diabetes has a greater detrimental effect on central nervous system development (76). Also, a number of studies have shown that glucose abnormalities are associated with impaired neurocognitive function (77), which may lead to psychiatric disorders. In addition, Sillanpää noted that poor social adjustment and reduced functioning in patients with T1DM may further increase their risk of developing major psychiatric disorders (78).

There may be some limitations to our analysis. First, the prevalence of mental developmental disorders among people with type 1 diabetes and the incidence of type 1 diabetes among people with mental developmental disorders may be underestimated, as there are still areas where low awareness of mental disorders or inadequate understanding of type 1 diabetes may lead to underdiagnosis and thus affect the accuracy of prevalence. Secondly, the literature is limited, and the results of our regional subgroup analysis for existing literature may not be applicable to all regions of the world. In addition, in the subgroup analysis results of prevalence of ASD in T1DM patients, the low prevalence in some age groups may lead to the unreliable prevalence of ASD in T1DM patients. However, mental disorders include six diseases, but there are few literatures related to some of them and more relevant researches are needed. Finally, recall bias can occur when recording situations through self-reports or parental reports.

In conclusion, this systematic review and meta-analysis suggests that type 1 diabetes is associated with the neurodevelopmental disorders in children and adolescents. There was a significant increase in the prevalence of ASD or ADHD in the adolescent T1DM population compared with that in the general population, and there was a trend for the prevalence of ASD and ADHD to increase with age in the T1DM population, but there is less literature on the association of the prevalence of T1DM in the children and adolescent neurodevelopmental disorders population. The potential link between the two disorders was also explored in this systematic review and meta-analysis, but the mechanisms behind T1DM and psychiatric disorders are not fully understood, and more high-quality studies are needed to elucidate the pathogenesis of T1DM and psychiatric disorders and to explore their intrinsic connections.

Data availability statement

The original contributions presented in this study are included in the article/Supplementary material, further inquiries can be directed to the corresponding author/s.

Author contributions

Y-ML and X-YL conceived the study design. C-YX and XL conducted data analysis. X-NX conducted study evaluation and wrote the manuscript. All authors have reviewed and approved the submitted version of the manuscript.

Funding

This study was funded by the National Natural Science Foundation of China (81873806).

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fpsyt.2022.982696/full#supplementary-material
How do child and adolescent mental health problems influence public sector costs?

Economic impact of childhood psychiatric disorder on public sector services in intellectual disability.

Willemsen MH, et al. Genome sequencing identifies major causes of severe neurodevelopmental disorders.

Prevalence and characteristics of autism spectrum disorder among children aged 8 years—autism and developmental disabilities monitoring network, 11 sites, United States, 2012. MMWR Surveill Summ. (2013) 62:1-19.

Maenner MJ, Shaw KA, Bakian AV, Bilder DA, Durkin MS, Esler A, et al. The co-morbidity burden of children and young adults with autism spectrum disorder among children with type 1 diabetes: a nationwide cohort study. Diabetes Med. (2019) 36:1288-6. doi: 10.1111/dme.15703

Butwicka A, Frisen L, Almqvist C, Zethelius B, Lichtenstein P. Risks of psychiatric disorders and suicide attempts in children and adolescents with type 1 diabetes: a population-based cohort study. Diabetes Care. (2015) 38:453-9. doi: 10.2337/dc14-0262

Buchberger B, Huppertz H, Krabbe L, Lux B, Mattivi JT, Safarikas A. Symptoms of depression and anxiety in youth with type 1 diabetes: a systematic review and meta-analysis. Psychoneuroendocrinology. (2016) 70:70-84. doi: 10.1016/j.pنس.2016.04.019

Cooper MN, Lin A, Alvaes GA, de Klerk NH, Jones TW, Davis EA. Psychiatric disorders during early adulthood in those with childhood onset type 1 diabetes: rates and clinical risk factors from population-based follow-up. Pediatr Diabetes. (2017) 18:599-606. doi: 10.1111/pedi.12469

Dybdal D, Tolestrup JS, Sildorf SM. Increasing risk of psychiatric morbidity after childhood onset type 1 diabetes: a population-based cohort study. Diabetologia. (2018) 61:813-8. doi: 10.1007/s00125-017-4517-7

Collins MM, Corcoran P, Perry II. Anxiety and depression symptoms in patients with diabetes. Diabet Med. (2009) 26:153-61. doi: 10.1111/j.1464-5491.2008.02648.x

Petrik F, Hardj J, Wittchen HU. Prevalence of psychiatric disorders in an onset cohort of adults with type 1 diabetes. Diabetes Metab Res Rev. (2003) 19:216-22. doi: 10.1002/dmr.374

Duke DC, Harris MA. Executive function, adherence, and glycemic control in adolescents with type 1 diabetes: a literature review. Curr Diab Rep. (2014) 14:532. doi: 10.1007/s11892-014-0532-y

Delamater AM, de Wit M, McDarby V, Malik J, Acrini CL. International society for pediatric and adolescent diabetes. ISPAD clinical practice guidelines 2014. Psychological care of children and adolescents with type 1 diabetes. Pediatr Diabetes. (2014) 20:223-44. doi: 10.1111/pedi.12409

Page MJ, McKenzie JE, Boussuyt PM, Burton I, Hoffmann TC, Mulcdow Z, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. J Clin Epidemiol. (2021) 134:178-89. doi: 10.1016/j.jclinepi.2021.02.003

Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. (2002) 21:1593-8. doi: 10.1002/sim.1186

Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ (1997) 315:629-34. doi: 10.1136/bmj.315.7109.629

Begg CB, Marumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. (1994) 50:1088-101. doi: 10.2307/2533446

Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics. (2000) 56:455-63. doi: 10.1111/j.0006-144x.2000.0455x

Fergusson L, Franklin V. The prevalence of type 1 diabetes and autistic spectrum disorder in highland region, Scotland, and its impact on glycaemic control and care needs. Pediatr Diabetes. (2019) 20:226.

Freeman SJ, Roberts W, Daneman D. Type 1 diabetes and autism: is there a link? Diabetes Care. (2005) 28:925-6. doi: 10.2337/diabetes.28.06.05.1552

Page MJ, McKenzie JE, Boussuyt PM, Burton I, Hoffmann TC, Mulcdow Z, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. J Clin Epidemiol. (2021) 134:178-89. doi: 10.1016/j.jclinepi.2021.02.003

Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. (2002) 21:1593-8. doi: 10.1002/sim.1186

Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ (1997) 315:629-34. doi: 10.1136/bmj.315.7109.629

Begg CB, Marumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. (1994) 50:1088-101. doi: 10.2307/2533446

Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics. (2000) 56:455-63. doi: 10.1111/j.0006-144x.2000.0455x

Fergusson L, Franklin V. The prevalence of type 1 diabetes and autistic spectrum disorder in highland region, Scotland, and its impact on glycaemic control and care needs. Pediatr Diabetes. (2019) 20:226.

Freeman SJ, Roberts W, Daneman D. Type 1 diabetes and autism: is there a link? Diabetes Care. (2005) 28:925-6. doi: 10.2337/diabetes.28.06.05.1552

Kohane IS, McMurry A, Weber G, MacFadden D, Rappaport L, Kunkel L, et al. The co-morbidity burden of children and young adults with autism spectrum disorders. PLoS One. (2012) 7:e33224. doi: 10.1371/journal.pone.0033224

Liu S, Kuja-Halkola R, Larsson H, Lichtenstein P, Ludvigsson JF, Svenson AM, et al. Neurodevelopmental disorders, glycemic control, and diabetic complications in type 1 diabetes: a nationwide cohort study. J Clin Endocrinol Metab. (2021) 106:e459-70. doi: 10.1210/clinem/dgab407

Liu S, Kuja-Halkola R, Larsson H, Lichtenstein P, Ludvigsson JF, Svenson AM, et al. Poor glycemic control is associated with increased risk of
neurodevelopmental disorders in childhood-onset type 1 diabetes: a population-based cohort study. *Diabetologia*. (2021) 64:767–77. doi: 10.1007/s00125-020-05372-5

42. Stanek K, Raymond JK, Majdi S. Prevalence and management of patients with type 1 diabetes and autism spectrum disorder. *Diabetes*. (2016) 65:A338–9. doi: 10.2337/db16-861-1374

43. Stanek KR, Youngkin EM, Pyle LL, Raymond JK, Dirscholl KA, Majidi S. Prevalence and management of patients with type 1 diabetes and autism spectrum disorder. *Diabetes*. (2019) 68:645–51.

44. Toijar J. Is there a connection between type 1 diabetes and autism? the prevalence of autism in children with type 1 diabetes and differences in phenotype and biomarkers at diabetes diagnosis. *Pediatr Diabetes*. (2019) 20:127.

45. Beizina N. Attention deficit hyperactivity disorder and metabolic control in adolescents with type 1 diabetes. *Pediatric Diabetes*. (2015) 16:137.

46. Castillo K. Prevalence of attention-deficit/hyperactivity disorder in children and adolescents with early onset type 1 diabetes compared to general population peers. *Pediatric Diabetes*. (2017) 18:52–3.

47. Chen HJ, Lee YJ, Yeh GC, Lin HC. Association of attention-deficit/hyperactivity disorder with diabetes: a population-based study. *Pediatr Res. (2013) 73:492–6.* doi: 10.1038/pr.2013.5

48. Duke DC. Not paying attention to diabetes: ADHD and diabetes management. *Pediatrics*. (2012) 61:A210.

49. Kapellen TM, Reimann R, Kiers W, Kostev K. Prevalence of medically treated children with ADHD and type 1 diabetes in Germany – analysis of two representative databases. *J Pediatr Endocrinol Metab*. (2016) 29:1293–7. doi: 10.1515/pejme-2016-0171

50. Landau Z. Dual diagnosis of type 1 diabetes and ADHD. *Pediatric Diabetes*. (2019) 20:225–6.

51. Lin SY, Lin CL, Hu WH, Lin CC, Fu YC. Association of attention deficit hyperactivity disorder with recurrent hypoglycemia in type 1 diabetes mellitus. *Pediatr Diabetes*. (2019) 20:189–96. doi: 10.1111/pedi.12716

52. Lindblad I, Engström AC, Nylander C, Fernald E. Adolescents with type 1 diabetes mellitus and attention-deficit/hyperactivity disorder require specific support from healthcare professionals. *Acta Paediatr*. (2017) 106:1994–7. doi: 10.1111/apa.13989

53. Macek I, Batellello T, Biejak M, Zupanc C, Bograf AK, Vesnic S, et al. Impact of attention deficit hyperactivity disorder on metabolic control in adolescents with type 1 diabetes. *J Psychosom Res.* (2019) 126:109816. doi: 10.1016/j.jpsychores.2019.109816

54. Mazor-Aronovitch K, Pinhas-Hamiel O, Pirko-Levy D, Modan-Moses D, Levek N, Miller S, et al. Dual diagnosis of type 1 diabetes and ADHD. *Hormone Res Paediatrics*. (2019) 91:88–9.

55. Nylander C, Lindström K, Khalfi N, Fernald E. Previously undiagnosed attention-deficit/hyperactivity disorder associated with poor metabolic control in adolescents with type 1 diabetes. *Pediatr Diabetes*. (2018) 19:816–22. doi: 10.1111/pedi.12651

56. Nylander C, Lindberg Y, Haas J, Svenne I, Torbjörnsdotter T, Åkesson K, et al. Self- and parent-reported executive problems in adolescents with type 1 diabetes are associated with poor metabolic control and low physical activity. *Pediatric Diabetes*. (2018) 19:98–105. doi: 10.1111/pedi.12520

57. Vinker-Shuster M, Eldor R, Green I, Golan-Cohen A, Manor I, Merzon E. Attention-deficit hyperactivity disorder in pediatric patients with type 1 diabetes mellitus: clinical outcomes and diabetes control. *J Dev Behav Pediatr.* (2019) 40:330–4. doi: 10.1097/DBP.0000000000000670

58. Xie et al. 10.3389/fpsyt.2022.982696